Literature DB >> 11448454

mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine.

D E Selley1, C C Cao, T Sexton, J A Schwegel, T J Martin, S R Childers.   

Abstract

The efficacy of heroin metabolites for the stimulation of mu opioid receptor-mediated G-protein activation was investigated using agonist-stimulated [(35)S]guanosine-5'-O-(gamma-thio)-triphosphate binding. In rat thalamic membranes, heroin and its primary metabolite, 6-monoacetylmorphine (6-MAM), were more efficacious than morphine or morphine-6-beta D-glucuronide. This increased efficacy was not due to increased action of heroin and 6-MAM at delta receptors, as determined by competitive antagonism by naloxone, lack of antagonism by naltrindole, and competitive partial antagonism with morphine. In agreement with this interpretation, the same relative efficacy profile of heroin and its metabolites was observed at the cloned human mu opioid receptor expressed in C6 glioma cells. Moreover, these efficacy differences were GDP-dependent in a manner consistent with accepted mechanisms of receptor-mediated G-protein activation. The activity of heroin was attributed to in vitro deacetylation to 6-MAM, as confirmed by HPLC analysis. These results indicate that the heroin metabolite 6-MAM possesses higher efficacy than other heroin metabolites at mu opioid receptors, which may contribute to the higher efficacy of heroin compared with morphine in certain behavioral paradigms in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448454     DOI: 10.1016/s0006-2952(01)00689-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  38 in total

1.  Rewarding electrical brain stimulation in rats after peripheral nerve injury: decreased facilitation by commonly abused prescription opioids.

Authors:  Eric E Ewan; Thomas J Martin
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

2.  Fundamental reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of heroin.

Authors:  Yan Qiao; Keli Han; Chang-Guo Zhan
Journal:  Biochemistry       Date:  2013-08-30       Impact factor: 3.162

Review 3.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

4.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

Review 5.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

6.  Protective role of taurine against morphine-induced neurotoxicity in C6 cells via inhibition of oxidative stress.

Authors:  Jiaqing Zhou; Yan Li; Guangyan Yan; Qian Bu; Lei Lv; Yanzhu Yang; Jinxuan Zhao; Xue Shao; Yi Deng; Ruimin Zhu; Yinglan Zhao; Xiaobo Cen
Journal:  Neurotox Res       Date:  2011-05-25       Impact factor: 3.911

7.  Vaccines to combat the opioid crisis: Vaccines that prevent opioids and other substances of abuse from entering the brain could effectively treat addiction and abuse.

Authors:  Margaret E Olson; Kim D Janda
Journal:  EMBO Rep       Date:  2017-12-13       Impact factor: 8.807

8.  Population pharmacokinetics of heroin and its major metabolites.

Authors:  Elisabeth J Rook; Alwin D R Huitema; Wim van den Brink; Jan M van Ree; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

9.  Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.

Authors:  M D Raleigh; M Pravetoni; A C Harris; A K Birnbaum; P R Pentel
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

10.  Acute and chronic heroin dependence in mice: contribution of opioid and excitatory amino acid receptors.

Authors:  Gad Klein; Aaron Juni; Caroline A Arout; Amanda R Waxman; Charles E Inturrisi; Benjamin Kest
Journal:  Eur J Pharmacol       Date:  2008-02-19       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.